Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: conix, Foxwoods Man, drkazmd65, The_Q
Search This Board: 
Last Post: 3/5/2021 6:26:38 PM - Followers: 352 - Board type: Free - Posts Today: 8

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4








Products In Development

 

 

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

https://www.prnewswire.com/news-releases/biotech-brief-growing-number-of-ongoing-clinical-trials-for-leukemia-aml-brings-new-hope-300827745.html

http://KillCVMShorts.com/faqs

http://KillCVMShorts.com/idmc

http://KillCVMShorts.com

http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

https://seekingalpha.com/instablog/50299941-cvm4life/5309598-setting-record-straight-cel-sci

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2

CVM shares held by iHub investors :

https://docs.google.com/spreadsheets/d/1aU3buYiKiQZDyNPRIBZWGoUk37TrlSjJ/edit#gid=1952396312

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2














 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Cel-Sci reports FQ1 results 02/16/2021 09:10:18 AM
CVM News: CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results 02/16/2021 09:00:00 AM
CVM News: Post-effective Amendment to Registration Statement (pos Am) 01/15/2021 05:11:12 PM
CVM News: CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference 01/08/2021 08:30:00 AM
CVM News: CEL-SCI Corporation Issues Letter to Shareholders 01/04/2021 09:15:00 AM
PostSubject
#34274  Sticky Note CEL-SCI Announces Update on Phase 3 Cancer Trial Results conix 12/07/20 09:48:46 AM
#19754  Sticky Note Welcome CVM Newbies sushifishman 04/06/19 08:25:19 AM
#36025   The clinical trial effect Biobonic 03/05/21 06:26:38 PM
#36024   I had read that article lightrock 03/05/21 06:13:50 PM
#36023   Israelis damaged by Vaccine: fluteman 03/05/21 04:54:09 PM
#36022   Cramer, he's a hustler. fluteman 03/05/21 01:21:39 PM
#36021   Cramer has a lot less pull in the RobotDroid 03/05/21 01:01:24 PM
#36020   Cramer likes immunotherapy stocks. He would include in conix 03/05/21 08:22:01 AM
#36019   Cramer last night on CVM "I think this fluteman 03/05/21 08:17:51 AM
#36018   Jim Cramer talks CVM: fluteman 03/05/21 08:10:11 AM
#36017   That is a very interesting observation that the lightrock 03/04/21 11:30:06 PM
#36016   James, I live in Oregon. And My name thinkingonlygreen 03/04/21 06:27:05 PM
#36015   Thank you for that explanation. I think frugalNorwegian 03/04/21 05:18:29 PM
#36014   @GD I like your gumption, but I think George sab63090 03/04/21 05:14:20 PM
#36013   An HLA article relevant to CelSci's P3 Trial jamesnhansen 03/04/21 04:48:20 PM
#36012   Agree with your speculation, hence my MAR bet, GD 03/04/21 04:10:45 PM
#36011   Perhaps Geert had to pull out of next meirluc 03/04/21 04:01:46 PM
#36010   GD for C sakes give yourself some margin georgebailey 03/04/21 03:11:23 PM
#36009   sushi, thanks for bringing the DD of Geert GD 03/04/21 02:23:36 PM
#36008   I'm sorry, I meant to say the 50 sab63090 03/04/21 02:17:19 PM
#36007   Divergence Between StageIII and StageIII/VIa Control Arms Explained jamesnhansen 03/04/21 02:10:06 PM
#36006   I did pick up more cvm at $17 RobotDroid 03/04/21 01:25:58 PM
#36005   Was going to say... lightrock 03/04/21 01:15:31 PM
#36004   What f$cked up market. RobotDroid 03/04/21 01:00:38 PM
#36003   Now Geert goes silent, of course. fluteman 03/04/21 12:40:50 PM
#36002   Volume sure is picking up this morning. See RobotDroid 03/04/21 10:32:55 AM
#36001   Jim - In your chart, you have the frugalNorwegian 03/04/21 09:52:41 AM
#36000   The 200 day magnet: sab63090 03/04/21 09:43:10 AM
#35999   Take a look! https://www.reddit.com/r/cvm/new/ frugalNorwegian 03/04/21 08:51:39 AM
#35998   GLSI is a Classic Case of "Bleached Tape." jamesnhansen 03/04/21 02:19:31 AM
#35997   look at GLSI Greenwich Lifesciences maverick35 03/04/21 01:05:53 AM
#35996   RobotDroid Posted, "In biotech land, there are leaks" jamesnhansen 03/04/21 12:05:11 AM
#35995   thx flute lightrock 03/03/21 09:25:20 PM
#35994   Seeking Alpha One Year Ago fluteman 03/03/21 07:54:15 PM
#35993   My bad lightrock 03/03/21 05:39:55 PM
#35992   Lightrock: I was addressing what Cramer & sab63090 03/03/21 05:22:10 PM
#35991   @Charmed Hope you bounce back in full recovery!!! sab63090 03/03/21 04:24:18 PM
#35990   Jim - Sounds good - I will get frugalNorwegian 03/03/21 04:11:53 PM
#35989   Sharing the Hansen CelSci OS Calculator with others. jamesnhansen 03/03/21 04:02:11 PM
#35988   CVM's Price Before and After the $41 Print jamesnhansen 03/03/21 03:46:34 PM
#35987   This is awesome! I just wanted to say Charmed7713 03/03/21 03:44:41 PM
#35986   Jim - I forgot to ask. Would frugalNorwegian 03/03/21 03:44:13 PM
#35985   Jim - nice job! Are you able frugalNorwegian 03/03/21 03:07:56 PM
#35984   For one, I don't look at it that lightrock 03/03/21 03:01:26 PM
#35983   looks interesting but substantial drop since Feb 1st timetravelerdos 03/03/21 02:55:08 PM
#35982   Fosco and Me: Twin sons of Different Mothers. jamesnhansen 03/03/21 02:40:32 PM
#35981   Very impressive, you must be a relative of greenJack 03/03/21 02:05:59 PM
#35980   Looks great ! lightrock 03/03/21 01:22:50 PM
#35979   Anybody who is not winning with puts and lightrock 03/03/21 01:07:58 PM
#35978   Is this option trade important? We'll soon see. jamesnhansen 03/03/21 01:05:17 PM
#35977   v2.0 of our CelSci P3 Overall Survival Calculator jamesnhansen 03/03/21 12:57:15 PM
#35976   The reason why short sellers do what they sab63090 03/03/21 12:44:34 PM
PostSubject
Consent Preferences